PT1846394E - Derivados de pirazolilaminopiridina úteis como inibidores da quinase - Google Patents

Derivados de pirazolilaminopiridina úteis como inibidores da quinase

Info

Publication number
PT1846394E
PT1846394E PT06701619T PT06701619T PT1846394E PT 1846394 E PT1846394 E PT 1846394E PT 06701619 T PT06701619 T PT 06701619T PT 06701619 T PT06701619 T PT 06701619T PT 1846394 E PT1846394 E PT 1846394E
Authority
PT
Portugal
Prior art keywords
kinase inhibitors
derivatives useful
pyrazolylaminopyridine
pyrazolylaminopyridine derivatives
useful
Prior art date
Application number
PT06701619T
Other languages
English (en)
Inventor
Michelle Lamb
Tao Wang
Dingwei Yu
Audrey Davies
Paul Lyne
Peter Mohr
Bin Wang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1846394E publication Critical patent/PT1846394E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
PT06701619T 2005-02-04 2006-02-01 Derivados de pirazolilaminopiridina úteis como inibidores da quinase PT1846394E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65005305P 2005-02-04 2005-02-04
US65332905P 2005-02-16 2005-02-16
US72163305P 2005-09-29 2005-09-29

Publications (1)

Publication Number Publication Date
PT1846394E true PT1846394E (pt) 2012-01-05

Family

ID=36177856

Family Applications (2)

Application Number Title Priority Date Filing Date
PT111673620T PT2383268E (pt) 2005-02-04 2006-02-01 Derivados de pirazolilaminopiridina úteis como inibidores de quinase
PT06701619T PT1846394E (pt) 2005-02-04 2006-02-01 Derivados de pirazolilaminopiridina úteis como inibidores da quinase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT111673620T PT2383268E (pt) 2005-02-04 2006-02-01 Derivados de pirazolilaminopiridina úteis como inibidores de quinase

Country Status (30)

Country Link
US (2) US8324252B2 (pt)
EP (2) EP1846394B1 (pt)
JP (1) JP5139084B2 (pt)
KR (1) KR101302945B1 (pt)
CN (1) CN101155800B (pt)
AR (1) AR056184A1 (pt)
AT (1) ATE530545T1 (pt)
AU (1) AU2006210710B2 (pt)
BR (1) BRPI0606793A8 (pt)
CA (1) CA2595834C (pt)
CY (2) CY1115078T1 (pt)
DK (2) DK1846394T3 (pt)
ES (2) ES2375735T3 (pt)
HK (2) HK1114374A1 (pt)
HR (1) HRP20110962T1 (pt)
HU (1) HUE025671T2 (pt)
IL (1) IL184674A (pt)
ME (1) ME02645B (pt)
MX (1) MX2007009437A (pt)
MY (1) MY149512A (pt)
NO (1) NO341112B1 (pt)
NZ (1) NZ561145A (pt)
PL (2) PL2383268T3 (pt)
PT (2) PT2383268E (pt)
RS (1) RS52061B (pt)
SA (1) SA06270007B1 (pt)
SI (2) SI2383268T1 (pt)
TW (1) TWI370127B (pt)
UY (1) UY29360A1 (pt)
WO (1) WO2006082392A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006087530A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
EP1899323A2 (en) * 2005-05-16 2008-03-19 AstraZeneca AB Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
BRPI0618011A2 (pt) 2005-10-28 2011-08-16 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
US20090275515A1 (en) * 2006-10-18 2009-11-05 Yuntae Kim 2-hydroxy-2-phenylthiophenylpropionamides as androgen receptor modulators
WO2008053812A1 (fr) * 2006-10-27 2008-05-08 Mitsubishi Tanabe Pharma Corporation Dérivé de cyanopyridine et son utilisation médicale
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
JP5524491B2 (ja) * 2008-03-04 2014-06-18 石原産業株式会社 3−アミノ−2−クロロ−6−トリフルオロメチルピリジンの製造方法
TW201011017A (en) * 2008-08-19 2010-03-16 Astrazeneca Ab Chemical compounds 495-1
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
KR101789129B1 (ko) 2010-06-30 2017-11-20 후지필름 가부시키가이샤 신규 니코틴아미드 유도체 또는 그 염
UY33517A (es) 2010-07-19 2012-02-29 Astrazeneca Ab Depósito farmacéutico para 5-fluoro-2-[[(1S)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1H-pirazol-3-il)amino]piridin-3-carbonitrilo?.
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
DK2799431T3 (en) 2011-12-28 2018-03-26 Fujifilm Corp Hitherto unknown nicotinamide derivatives or salts thereof
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物
CN107868071B (zh) * 2012-11-05 2021-07-20 爱默蕾大学 7,8-二羟黄酮和7,8-取代的黄酮衍生物、组合物及其相关方法
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
HRP20211813T1 (hr) 2014-08-11 2022-03-04 Acerta Pharma B.V. Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
ES2921875T3 (es) 2014-08-11 2022-09-01 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor BTK, un inhibidor PD-1 y/o un inhibidor PD-L1
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
US20190053492A1 (en) 2016-03-16 2019-02-21 Bayer Cropscience Aktiengesellschaft Substituted pyridine compounds as pesticides
US20220235013A1 (en) 2017-03-21 2022-07-28 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
US20220274979A1 (en) 2018-04-18 2022-09-01 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
US20220235070A1 (en) 2019-05-21 2022-07-28 Zhejiang Hisun Pharmaceutical Co., Ltd. Macrolide derivatives, preparation method and application thereof
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
TR199801530T2 (xx) 1996-02-13 1998-11-23 Zeneca Limited VEGF �nhibit�rleri olarak kinazolin t�revleri.
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド 4―アニリノキナゾリン誘導体
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
CA2321153A1 (en) 1998-02-17 1999-08-19 Timothy D. Cushing Anti-viral pyrimidine derivatives
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
DE19917785A1 (de) 1999-04-20 2000-10-26 Bayer Ag 2,4-Diamino-pyrimidin-Derivate
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
BR0013899A (pt) 1999-09-10 2003-07-08 Merck & Co Inc Composto, composição farmacêutica, processos de tratamento ou prevenção de câncer, de uma doença em que a angiogênese esteja implicada, da vascularização retinal, da retinopatia diabética, da degeneração macular relacionada a idade, de doenças inflamatórias, de uma doença ou condições dependentes da tirosina quinase, de patologias associadas com ossos, e, processos para produzir uma composição farmacêutica, e de reduzir ou prevenir dano tecidual em seguida a um evento isquêmico cerebral
EP1246823A1 (en) 1999-12-28 2002-10-09 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
WO2001060816A1 (en) 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
DK1282607T3 (en) 2000-05-08 2016-02-01 Janssen Pharmaceutica Nv Prodrugs of HIV replication inhibiting pyrimidines
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
BR0112225A (pt) 2000-07-07 2003-05-06 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto
CN1518543A (zh) 2000-08-31 2004-08-04 �Ʒ� 吡唑衍生物和它们作为蛋白激酶抑制剂的用途
WO2002020513A1 (en) 2000-09-01 2002-03-14 Glaxo Group Limited Oxindole derivatives
WO2002020479A1 (en) 2000-09-01 2002-03-14 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
AU2001292670A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ATE318812T1 (de) 2000-12-21 2006-03-15 Bristol Myers Squibb Co Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie
BR0116411A (pt) 2000-12-21 2003-11-11 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
ES2275021T3 (es) 2001-09-27 2007-06-01 Smithkline Beecham Corporation Derivados de azoxoindol como inhibidores de trk proteina quinasa para el tratamiento de cancer y dolor cronico.
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US20090227648A1 (en) 2004-04-21 2009-09-10 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
AU2005289426A1 (en) 2004-09-27 2006-04-06 Amgen Inc. Substituted heterocyclic compounds and methods of use
CA2588220A1 (en) 2004-12-23 2006-06-29 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
EP1841760B1 (en) 2004-12-30 2011-08-10 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
ES2347172T3 (es) 2005-02-16 2010-10-26 Astrazeneca Ab Compuestos quimicos.
WO2006087530A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
WO2006115452A1 (en) 2005-04-27 2006-11-02 Astrazeneca Ab Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
CA2607727A1 (en) 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
JP2008540391A (ja) 2005-05-05 2008-11-20 アストラゼネカ アクチボラグ ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用
EP1899323A2 (en) 2005-05-16 2008-03-19 AstraZeneca AB Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
BRPI0618011A2 (pt) 2005-10-28 2011-08-16 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
AU2007263655A1 (en) 2006-06-30 2008-01-03 Astrazeneca Ab Pyrimidine derivatives useful in the treatment of cancer
TW200826937A (en) 2006-11-01 2008-07-01 Astrazeneca Ab New use
TW200823196A (en) 2006-11-01 2008-06-01 Astrazeneca Ab New use

Also Published As

Publication number Publication date
US20130090358A1 (en) 2013-04-11
HRP20110962T1 (hr) 2012-01-31
EP2383268B1 (en) 2015-09-02
CY1119077T1 (el) 2018-01-10
CN101155800A (zh) 2008-04-02
NO341112B1 (no) 2017-08-28
EP1846394B1 (en) 2011-10-26
CA2595834A1 (en) 2006-08-10
TWI370127B (en) 2012-08-11
BRPI0606793A2 (pt) 2009-12-01
MY149512A (en) 2013-09-13
MX2007009437A (es) 2007-08-16
CA2595834C (en) 2013-04-30
IL184674A (en) 2012-07-31
ME02645B (me) 2012-04-30
HK1163677A1 (zh) 2012-09-14
BRPI0606793A8 (pt) 2018-03-13
DK2383268T3 (en) 2015-09-14
NZ561145A (en) 2011-02-25
KR20070107107A (ko) 2007-11-06
CN101155800B (zh) 2012-05-23
NO20073791L (no) 2007-08-30
US8324252B2 (en) 2012-12-04
IL184674A0 (en) 2007-12-03
EP1846394A1 (en) 2007-10-24
ES2555063T3 (es) 2015-12-28
JP2008528664A (ja) 2008-07-31
SA06270007B1 (ar) 2010-11-22
HK1114374A1 (en) 2008-10-31
US20080139561A1 (en) 2008-06-12
UY29360A1 (es) 2006-10-02
HUE025671T2 (en) 2016-04-28
PT2383268E (pt) 2015-12-21
JP5139084B2 (ja) 2013-02-06
AU2006210710B2 (en) 2009-12-10
AU2006210710A1 (en) 2006-08-10
SI2383268T1 (sl) 2016-02-29
DK1846394T3 (da) 2012-01-16
ES2375735T3 (es) 2012-03-05
SI1846394T1 (sl) 2012-06-29
EP2383268A1 (en) 2011-11-02
PL2383268T3 (pl) 2016-02-29
ATE530545T1 (de) 2011-11-15
CY1115078T1 (el) 2016-12-14
KR101302945B1 (ko) 2013-09-06
AR056184A1 (es) 2007-09-26
US8835465B2 (en) 2014-09-16
WO2006082392A1 (en) 2006-08-10
RS52061B (en) 2012-04-30
PL1846394T3 (pl) 2012-04-30

Similar Documents

Publication Publication Date Title
TWI370127B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
HK1114380A1 (en) Pyrrolopyrazoles as kinase inhibitors
IL186845A0 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
EP1948193A4 (en) AMINOPYRIMIDINES SUITABLE AS KINASEINHIBITORS
IL190078A0 (en) Kinase inhibitors
IL189194A0 (en) Substituted benzimidazoles as kinase inhibitors
IL177278A0 (en) Pyrazolotriazines as kinase inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
HK1107348A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
IL187310A0 (en) Bicyclic derivatives as p38 kinase inhibitors
EP2046333A4 (en) THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE
SI1943243T1 (sl) Inhibotorji kinaz
EP1778693A4 (en) AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL
IL188027A0 (en) Bicyclic derivatives as p38 kinase inhibitors
HK1112918A1 (en) Benzofuranyl derivatives as 5-ht6-receptor inhibitors
ZA200800506B (en) Substituted benzimidazoles as kinase inhibitors
ZA200709732B (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
ZA200804600B (en) Aminopyrimidines useful as kinase inhibitors
ZA200706212B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EP1940411A4 (en) MACROHETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
IL189985A0 (en) Kinase inhibitors
ZA200803287B (en) Kinase inhibitors